July 10, 2010 in Nation/World

FDA criticizes diabetes pill study

‘Serious flaws’ found in report on Avandia
Matthew Perrone Associated Press
 

WASHINGTON – Federal health scientists have panned a GlaxoSmithKline study that the company used to defend the safety of its embattled diabetes drug Avandia, a once blockbuster-seller that has fallen out of favor because of potential ties to heart attacks.

The Food and Drug Administration posted an exhaustive 700-page review of Avandia on Friday ahead of a meeting next week to decide whether the drug should stay on the market.

The FDA finds itself in a difficult position that’s all too familiar: reviewing a drug approved a decade ago that now appears tied to deadly side effects. Experts say the FDA’s predicament is a result of shifting standards for the agency: increased scrutiny on safety and stepped-up pressure from Capitol Hill.

The FDA reviewed dozens of studies of Avandia, including one Glaxo has pointed to as proof of the drug’s safety. But an FDA reviewer said the study was plagued by “serious flaws” and actually supports the case against Avandia.

The drug works by increasing the body’s sensitivity to insulin, a key protein needed for digestion that diabetics don’t adequately produce.

Glaxo, based in London, has argued for years that Avandia’s safety should be assessed only based on clinical trials, considered the gold standard of medical research.

But the FDA reviewer said Glaxo’s chief trial “was inadequately designed and conducted to provide any reassurance” about the heart safety of Avandia.

The FDA holds a special two-day meeting starting Tuesday to help decide what course of action to take. A panel of outside physicians will consider a range of recommendations including:

• Adding more warning labels.

• Limiting which doctors can prescribe the drug.

• Pulling the drug from the market.

The FDA is not required to follow the advice of its outside panels, though it usually does.

New data on Avandia’s risks and pressure from politicians have prompted the agency to re-examine the drug’s safety.

© Copyright 2010 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.


There is one comment on this story. Click here to view comment >>

Get stories like this in a free daily email